« Patients with polycythemia vera (PV) require life-long treatment to prevent thromboembolic events and minimize the risk of progression. Ropeginterferon alpha-2b (BESREMi®; hereafter ropeg) may ultimately modify the natural history of PV by selectively targeting the malignant clone. In the PROUD-PV/CONTINUATION-PV studies, long-term treatment with ropeg was compared with standard cytoreductive therapy regarding thromboembolic and other adverse events as well as evolution of hematologic and molecular parameters over five years. »
Long-Term Use of Besremi in Polycythemia Vera: 5... - MPN Voice
Long-Term Use of Besremi in Polycythemia Vera: 5-Year Results from a Randomized Controlled Study and Its Extension
Thank you. Very encouraging 😊
Thanks for posting. This is encouraging. I wonder if those of us on Pegasys will be able to switch over?
More promising data for the use of Besremi. Besremi was mentioned in the recent MPN Advocacy Intl. Webinar with hope that it will be much easier for PV patients to access the drug once it is FDA approved for PV. Hopefully it will be so.
Anyone know when it’s coming to the USA?
Is there any country that Besremi is already approved???
Germany approved it and it has been in use since late 2019. I believe it has been approved by the EU as a whole and also some Asian countries
So here in Greece ( Europe) do we have Besremi approved for PV?
Hi l think so as it was approved by the EU body for all 28 states plus Norway Iceland
Many thanks for posting this link Manouche.
Thank you for sharing